API | cerlapirdine

cerlapirdine Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Cerlapirdine is a drug which was under development by Wyeth/Pfizer for the treatment of cognitive disorders associated with Alzheimer's disease and schizophrenia. In a phase II clinical trial it demonstrated a trend toward efficacy along with a good side effect profile and no incidence of serious adverse events, but no further development has occurred since 2011. ^Wikipedia

Chemistry

SMILES: CN(C)CCCOc1ccc2[nH]nc(S(=O)(=O)c3cccc4ccccc34)c2c1
InChIKey: NXQGEDVQXVTCDA-UHFFFAOYSA-N
Mol. Mass: 409.51
ALogP: 3.88 Partition coefficient
ChEMBL Molecule:
cerlapirdine

More Chemistry

Pharmacology

Mechanism of Action:
- 5-hydroxytryptamine receptor 6 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

cerlapirdine | pf-05212365 | sam-531 | way-262531

Organizations (3)

Research & Development (3)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Adult (Phase 1)

Alzheimer Disease (Phase 2)

Healthy Volunteers (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 12
# of Trial Organizations: 3

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue